Abstract
Chemotherapy-induced neuropathic pain is a significant side effect of chemotherapeutic agents and is the most common reason for stopping chemotherapy. The aim of the present study was to find the major site and mechanisms of action by which rolipram, a selective phosphodiesterase-4 inhibitor, alleviates paclitaxel-induced neuropathic pain. Chemotherapy-induced neuropathic pain was induced in adult male Sprague-Dawley rats by intraperitoneal injection of paclitaxel on four alternate days. Rolipram was administered systemically or locally into the lumbar spinal cord, L5 dorsal root ganglion, sciatic nerve, or skin nerve terminal. The mechanical threshold, the protein level of several inflammatory cytokines, and the cellular locations of phosphodiesterase-4 and interleukin-1β in the dorsal root ganglion were measured by using behavioral testing, Western blotting, and immunohistochemistry, respectively. The local administration (0.03-mg) of rolipram in the L5 dorsal root ganglion ameliorated paclitaxel-induced pain behavior more effectively than did local administration in the other sites. Paclitaxel significantly increased the expression of inflammatory cytokines including tumor necrosis factor-α (2.2 times) and interleukin-1β (2.7 times) in the lumbar dorsal root ganglion, and rolipram significantly decreased it. In addition, phosphodiesterase-4 and interleukin-1β were expressed in the dorsal root ganglion neurons and satellite cells and paclitaxel significantly increased the intensity of interleukin-1β (2 times) and rolipram significantly decreased it. These results suggest that the major site of action of rolipram on paclitaxel-induced neuropathic pain in rats was the dorsal root ganglion. Rolipram decreased the expression of inflammatory cytokines in the dorsal root ganglion. Thus, phosphodiesterase-4 inhibitors may ameliorate chemotherapy-induced neuropathic pain by decreasing expression of inflammatory cytokines in the dorsal root ganglion.
Highlights
Many chemotherapy drugs, including taxanes, platinum-based agents, vinca alkaloids, bortezomib, thalidomide, lenalidomide, suramin, and epothilones, produce a syndrome called chemotherapyinduced neuropathic pain, whose symptoms include ongoing burning pain, tingling, and numbness in the glove and stocking areas of the hands and legs (Massey et al, 2014; Kim et al, 2015b)
These data indicate that the L5 dorsal root ganglion (DRG) was a major site of action for rolipram in paclitaxel-induced neuropathic pain in rats
These findings indicate that rolipram decreased inflammatory cytokines in the DRGs
Summary
Many chemotherapy drugs, including taxanes (paclitaxel, docetaxel), platinum-based agents (cisplatin, carboplatin, oxaliplatin), vinca alkaloids (vincristine, vinblastine, vindesine, vinorelbine), bortezomib, thalidomide, lenalidomide, suramin, and epothilones, produce a syndrome called chemotherapyinduced neuropathic pain, whose symptoms include ongoing burning pain, tingling, and numbness in the glove and stocking areas of the hands and legs (Massey et al, 2014; Kim et al, 2015b). The phosphodiesterases are a group of enzymes that degrade the phosphodiester bond of secondary messengers such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate and terminate their own action.(Houslay and Adams, 2003) PDE4, which is mainly found in nerve cells and immune cells, hydrolyzes only cAMP (Houslay and Adams, 2003). By inhibiting PDE4, rolipram increases the amount of cAMP in nerve cells and immune cells. Increased levels of cAMP inhibit proinflammatory processes such as chemotaxis, degradation, and phagocytosis (Ottonello et al, 1995; Rossi et al, 1998; Pryzwansky and Madden, 2003; Pearse et al, 2004). Rolipram inhibits inflammation in both nerve cells and immune cells through increasing cAMP levels
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
